Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects by Peeters, R.P. (Robin) et al.
Polymorphisms in Thyroid Hormone Pathway Genes Are
Associated with Plasma TSH and Iodothyronine Levels
in Healthy Subjects
ROBIN P. PEETERS, HANS VAN TOOR, WILLEM KLOOTWIJK, YOLANDA B. DE RIJKE,
GEORGE G. J. M. KUIPER, ANDRE G. UITTERLINDEN, AND THEO J. VISSER
Departments of Internal Medicine (R.P.P., H.v.T., W.K., Y.B.d.R., G.G.J.M.K., A.G.U., T.J.V.), Clinical Chemistry (Y.B.d.R.,
A.G.U.), and Epidemiology and Biostatistics (A.G.U.), Erasmus University Medical Center, Rotterdam, 3000 DR
The Netherlands
Single nucleotide polymorphisms (SNPs) in genes involved in
thyroid hormone metabolism may affect thyroid hormone bio-
activity. We investigated the occurrence and possible effects
of SNPs in the deiodinases (D1–D3), the TSH receptor (TSHR),
and the T3 receptor  (TR) genes.
SNPs were identified in public databases or by sequencing
of genomic DNA from 15 randomly selected subjects (30 al-
leles). Genotypes for the identified SNPs were determined in
156 healthy blood donors and related to plasma T4, free T4, T3,
rT3, and TSH levels.
Eight SNPs of interest were identified, four of which had
not yet been published. Three are located in the 3-untrans-
lated region: D1a-C/T (allele frequencies, C  66%, T  34%),
D1b-A/G (A  89.7%, G  10.3%), and D3-T/G (T  85.5%,
G  14.2%). Four are missense SNPs: D2-A/G (Thr92Ala, Thr 
61.2%, Ala  38.8%), TSHRa-G/C (Asp36His, Asp  99.4%,
His  0.6%), TSHRb-C/A (Pro52Thr, Pro  94.2%, Thr  5.8%),
and TSHRc-C/G (Asp727Glu, Asp  90.7%, Glu  9.3%). One is
a silent SNP: TR-T/C (T  96.8%, C  3.2%). D1a-T was asso-
ciated in a dose-dependent manner with a higher plasma rT3
[CC, 0.29  0.01; CT, 0.32  0.01; and TT, 0.34  0.02 nmol/liter
(mean  SE); P  0.017], a higher plasma rT3/T4 (P  0.01), and
a lower T3/rT3 (P  0.003) ratio. The D1b-G allele was associ-
ated with lower plasma rT3/T4 (P  0.024) and with higher
T3/rT3 (P  0.08) ratios. TSHRc-G was associated with a lower
plasma TSH (CC, 1.38  0.07, vs. GC, 1.06  0.14 mU/liter; P 
0.04), and with lower plasma TSH/free T4 (P  0.06), TSH/T3
(P  0.06), and TSH/T4 (P  0.08) ratios. No associations with
TSH and iodothyronine levels were found for the other SNPs.
We have analyzed eight SNPs in five thyroid hormone path-
way genes and found significant associations of three SNPs in
two genes (D1, TSHR) with plasma TSH or iodothyronine lev-
els in a normal population. (J Clin Endocrinol Metab 88:
2880–2888, 2003)
THYROID HORMONES PLAY an essential role in a va-riety of metabolic and developmental processes in the
human body. Most effects are mediated by the active thyroid
hormone T3 via a mechanism of T3-regulated gene expression
(1). Examples are the effects of thyroid hormone on brain
development and skeletal maturation, on heat production
and oxygen consumption, on the secretion and metabolic
turnover of different hormones, and on the contractility of
the heart (2–6). Production of thyroid hormone, in particular
the prohormone T4, is controlled by the classic hypothalamic-
pituitary-thyroid axis, whereas the biological activity of thy-
roid hormone, i.e. the availability of T3, is largely regulated
by the iodothyronine deiodinases D1, D2, and D3 (4, 7, 8).
Polymorphisms (variations in the nucleotide sequences of
the genome that occur in at least 1% of the population) in one
or more genes involved in thyroid hormone metabolism may
have subtle effects on thyroid hormone levels and thyroid
hormone bioactivity throughout life. The symptoms of sub-
clinical hyper- and hypothyroidism show that minor changes
in thyroid hormone levels can have important consequences
for quality of life, cognition, cholesterol metabolism, heart
rate, bone mineral density, and atherosclerosis (9–14). For
this reason, we investigated genes encoding key proteins in
thyroid hormone metabolism for the occurrence of single
nucleotide polymorphisms (SNPs). The genes selected in-
clude the three selenodeiodinase genes D1, D2, and D3, the
genes for the TSH receptor (TSHR), and the T3 receptor 
(TR). These genes were screened for SNPs, preferentially
those located in exons, by searching the public SNP database
(dbSNP), the human expressed sequence tag database
(dbEST), as well as the literature.
D1, D2, and D3 contain a selenocysteine (SeC) in their
catalytic center, encoded by a UGA codon (15–17). In the vast
majority of mRNAs, UGA is recognized as a stop codon. The
incorporation of SeC into the deiodinases requires the pres-
ence of a SeC insertion sequence (SECIS) element in the
3-untranslated region (UTR) of the mRNA and several trans-
acting factors (18). Because a SNP in this region may have
important consequences for the production of functional
deiodinase, the D1, D2, and D3 SECIS elements were se-
quenced in 15 randomly selected healthy subjects. Because
little information is available in the databases about the pos-
sible polymorphisms in human D3, we also decided to an-
alyze the coding sequence of the human D3 gene in these 15
subjects. A population of 156 healthy blood donors was geno-
typed with regard to these SNPs, and for each polymorphism
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SNP database; DTT, dithiothreitol; EST, expressed sequence tag; FT4,
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polymorphism; SBE, single base extension; SeC, selenocysteine; SECIS,
SeC insertion sequence; SNP, single nucleotide polymorphism; TR, T3
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the genotype was correlated with a specific set of plasma
thyroid indexes.
For the SNPs in the three deiodinases, we analyzed
correlations with plasma T4, T3, and rT3 and with iodo-
thyronine ratios. Plasma iodothyronine levels depend not
only on the activities of iodothyronine-metabolizing en-
zymes but also, among other things, on thyroid function
and plasma iodothyronine-binding capacity. Therefore,
ratios between plasma iodothyronines are thought to bet-
ter reflect tissue deiodinase activities. Local D2 activity is
essential for the negative feedback regulation of hypo-
physeal TSH secretion by plasma T4, as demonstrated in
the D2 knockout mouse (19). Therefore, the relation be-
tween the D2 SNP and plasma TSH, and TSH/T4 and
TSH/free T4 (FT4) ratios was also analyzed. For the SNPs
in the TSHR and in TR, we analyzed the correlation with
plasma iodothyronines and TSH levels, and with the ratios
thereof.
Subjects and Methods
Study population
Blood was collected from 158 healthy anonymized blood donors at
the Sanquin Blood Bank South West region (Rotterdam, The Nether-
lands). Informed consent was given by all donors. One subject was
excluded because of plasma FT4 and TSH levels indicating hyperthy-
roidism, another because of hypothyroid FT4 and TSH levels. Gender
was not documented for one subject. The study population thus con-
sisted of 100 males and 55 females with an average age of 46.2  12.2
yr (mean  sd); 47.4  10.9 yr in the males, and 44.6  13.9 yr in the
females. Donors on thyroid hormone treatment are not excluded from
blood donation. Although ethnic background of donors has not been
documented, over 99% may be of Caucasian origin. Descriptive statistics
of this population are shown in Table 1.
Plasma analyses
Plasma T4, FT4, T3, and TSH were measured by chemoluminescence
assays (Vitros ECI Immunodiagnostic System, Ortho-Clinical Diagnos-
tics, Amersham, Buckinghamshire, UK). rT3 was measured by RIA as
previously described (20).
DNA isolation
DNA was extracted from 2 ml of blood using the PUREGENE DNA
Isolation Kit (Gentra Systems, Minneapolis, MN) with slight modifica-
tions of the provided protocol. After isolation, DNA concentration was
measured at 260 nm, and all samples were diluted to a concentration of
50 ng/liter (stock) and 10 ng/l (work solution). Purity was determined
by measuring the 260/280-nm ratio.
Sequence analysis
DNA from 15 random subjects was used for sequence analysis. The
SECIS-element and flanking regions were analyzed in the D1, D2, and
D3 genes. At first, DNA was amplified by PCR using the primers listed
in Table 2. All primers used in this study were ordered from Invitrogen
(Breda, The Netherlands). The PCR was performed in a GeneAmp PCR
system 9700 Thermocycler (Applied Biosystems, Nieuwerkerk aan den
IJssel, The Netherlands), and conditions were as follows: 5 min at 96 C;
35 cycles of 1 min at 94 C, 1 min at annealing temperature (Table 2), and
1 min at 72 C; and finally, 7 min at 72 C. PCR products were verified by
agarose gel electrophoresis. Subsequently, they were purified using the
High Pure PCR Product Purification Kit (Roche Diagnostics, Almere,
The Netherlands). To increase specificity, sequencing of the PCR prod-
ucts was performed using internal primers (Table 2). Samples were
purified using Micro Bio-Spin P-30 Tris columns (Bio-Rad Laboratories,
Inc., Veenendaal, The Netherlands), and sequenced directly on an au-
tomated ABI 310 capillary sequencer (Applied Biosystems), using the
Big Dye Terminator Cycle Sequencing method (Applied Biosystems).
Database searches
Nucleotide sequences of the genes of interest were obtained from the
National Center for Biotechnology Information (NCBI; http://www.
ncbi.nlm.nih.gov). The TBLASTN program was used to search the
dbEST for sequences that differ in one or more nucleotides from the
wild-type (WT) gene. To exclude sequencing artifacts, at least two ESTs
with the same nucleotide difference were required before this variation
was marked as a potential SNP. In addition, the SNP database of NCBI
(dbSNP) was searched.
Restriction fragment length polymorphism (RFLP) analysis
PCR-RFLP procedures were developed for the D1a-C/T, D1b-A/G,
D2-Thr/Ala, D3-T/G, TSHRa-Asp/His, TSHRb-Pro/Thr, and TSHRc-
Asp/Glu polymorphisms. The primers used are listed in Table 3. For
D2-A/G, a mismatch primer was used to destroy a second restriction site
for RsaI. For D3-T/G and TSHRb-C/A, mismatch primers were used to
generate restriction sites for BssSI and Tth 111 I, respectively. The RFLP
for TSHRb-C/A was described previously (21). Twenty nanograms of
genomic DNA were amplified in a PCR with a total volume of 10 l. The
PCR mixture contained 1 PCR buffer (Invitrogen), 0.2 mm of each
TABLE 1. Descriptive statistics of the population analyzed in
this study
Parameter Mean  SDa Reference valuesb
n 155
Age 46.3  12.2c
TSH (mU/liter) 1.32  0.75d 0.4–4.3
T4 (nmol/liter) 87.96  15.9 58–128
FT4 (pmol/liter) 15.06  2.4 11–25
T3 (nmol/liter) 1.96  0.24 1.43–2.51
rT3 (nmol/liter) 0.31  0.08 0.14–0.34
a TSH and iodotyronine levels of this population were determined
in plasma.
b Reference values used in our lab, with TSH and iodothyronine
levels determined in serum.
c n  156, d n  154.
TABLE 2. Conditions used for PCR amplification and subsequent sequencing of gDNA regions of interest
Primers PCR Annealingtemperature Sequencing PCR product
SECIS-D1 Fw 5-TGAAATCTTCCACTAGCCTCA-3 50C 5-CAACAGAGTCATCTAGAAGGGA-3
Rv 5-ACTCCAGCAGGAGTTCATAAG-3 5-CACATTTAACATGTAACATAG-3
SECIS-D2 Fw 5-AAGCCAACAGGTAAACACATA-3 45C 5-CCAGGCCCATGTCACTGGTCA-3
Rv 5-AATACAAGAACAAATTGTATA-3 5-CACACATAGCACTCAGCACCA-3
SECIS-D3 Fw 5-AGTGCTTTGCCCGGTGCTTC-3 50C 5-GCTGCACAGAGACCTTGGCCA-3
Rv 5-CACCAAATGGCCTTCGAATCA-3 5-AATCAGCAGCTCTGCCTAGGA-3
D3-CDS1 Fw 5-CCCAGATGCCTCGCCAGGCCA-3 58C 5-TGGTCGGAGAGGGCGAGGGGTC-3
Rv 5-GCGCTCATGCGCGCCATGAA-3 5-TGCAGCTGCCGAAATTGAGAA-3
D3-CDS2 Fw 5-TTCTTCAAGCAGGCGCACGA-3 52C 5-CTCCGAGGTGGTTCTGCCCGA-3
Rv 5-CGCTTGCACGTGGGCTTCGAA-3 5-CTCGAAGGCCCAGCCCACCAA-3
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deoxynucleoside triphosphate, 1.5 mm MgCl2, 2 pmol of each primer,
and 0.5 U Taq polymerase (Invitrogen). Annealing temperatures of the
different PCRs are listed in Table 3. Five units of restriction enzyme were
used for a 1-h digestion of the PCR product at the recommended tem-
perature. Table 3 lists the restriction enzymes used for RFLP analysis of
the different SNPs. Digestion products were analyzed by agarose gel
electrophoresis. All subjects were genotyped for the D1a-C/T, D1b-
A/G, D2-Thr/Ala, D3-T/G, TSHRa-Asp/His, TSHRb-Pro/Thr, and
TSHRc-Asp/Glu polymorphisms using RFLP (see Fig. 2 for examples).
Single base extension (SBE) analysis
To validate the genotypes, two independent methods were used. In
addition to RFLP, genotyping was also performed by SBE analysis. All
subjects were genotyped for the D1a-C/T, D1b-A/G, D2-Thr/Ala, D3-
T/G, TSHRb-Pro/Thr, TSHRc-Asp/Glu, and TR-T/C polymorphisms
using SBE. PCR products were generated using the same primers as used
for RFLP analysis (Table 3), except for TSHRb and TR. A PCR fragment
of TSHR1b was generated using 5-ATTTCGGAGGATGGAGA-
AATA-3 as the forward primer and 5-GCAGATGCCCTTGAT-
CTCTG-3 as the reverse primer. Annealing temperature was 58 C. For
TR1, 5-TGCCTGTGTTGAGAGAATAG-3 was used as the forward
primer and 5-GTCTAATCCTCGAACACTTC-3 as the reverse primer;
annealing temperature was 51 C. All other conditions were the same as
mentioned above for the other PCRs. The SBE reactions were performed
using the ABI Prism SNaPshot ddNTP Primer Extension Kit (Applied
Biosystems) with slight modifications of the protocol provided by the
manufacturer. For SBE analysis of the D1a, D3, and TSHRb SNPs, the
reverse primers were used, and for the other SNPs the forward primers
were used.
Functional characterization of D2-Thr92Ala variant
A human D2 expression vector (pcDNA3-hD2-rSECIS), containing
the human D2 cDNA inserted 5 to the SECIS element of the rat D1 gene,
was used as template for site-directed mutagenesis via the circular
mutagenesis procedure (22, 23). Overlapping sense and antisense prim-
ers containing the nucleotide changes needed to produce the Thr92Ala
D2 mutant (sense 5-GTGCATGTCTCCAGTGCAGAAGGAGGT-
GACAAC) cDNA were used in circular mutagenesis reactions with 50
ng plasmid template and 2 U Pfu DNA polymerase (23). Plasmid DNA
isolated from five clones was sequenced directly on an automated ABI
310 capillary sequencer to verify that the desired mutation had been
generated and that no spurious mutations had occurred during
amplification.
The WT and variant D2 enzymes were expressed in COS cells (65-cm2
dishes) by diethylaminoethane-dextran-mediated transfection with 8g
plasmid DNA (22). After 2 d, the cells were rinsed with PBS and collected
in 0.25 ml PE buffer [0.1 m phosphate (pH 7.2), 2 mm EDTA], sonicated,
aliquoted, and stored at 80 C.
The principle of the in vitro D2 activity assay is the production of
radioiodide by outer-ring deiodination of [3,5-125I]T4 or [3,5-
125I]rT3.
Duplicate incubations contained about 100,000 cpm labeled T4 or rT3
with varying amounts of unlabeled substrate (T4 or rT3) and COS cell
homogenates (50–100 g protein) in a total volume of 0.2 ml of PED20
buffer [20 mm dithiothreitol (DTT)]. Mixtures were incubated for 60 min
at 37 C, whereafter the production of radioiodide was determined as
described (22).
The principle of the in situ D2 activity assay is the release of [125I]T3
in the medium of D2 expressing COS-1 cells incubated with [3,5-125I]T4.
COS cells were cultured in 6-well plates and transfected with 2.5 g of
plasmid per well as described (22). One day after transfection, cell
monolayers were washed with serum-free DMEM/F12 medium and
then cultured for an additional 24 h in serum-free DMEM/F12 (plus 40
nm selenite), to which were added [125I]T4 (10
6 cpm/ml) and 1–1000 nm
unlabeled T4. Medium was harvested, extracted, and analyzed by HPLC
as described (22).
Statistical analysis
Data were analyzed using SPSS 10.0.7 for Windows (SPSS, Inc., Chi-
cago, IL). Logarithmic transformations were applied to normalize vari-
ables and to minimize the influence of outliers if applicable. Differences
in plasma thyroid hormone levels between the genotype groups were
adjusted for age and sex and tested by analysis of covariance using the
general linear model procedure. Results are reported as mean  se in
the figures, and as mean  sd in the tables. Comparison of the frequen-
cies of the genotypes between males and females was carried out using
a 2 test. Deviation from Hardy-Weinberg equilibrium was also ana-
lyzed using a 2 test. P values are two-sided throughout, and P less than
0.05 was considered significant. Haplotype allele frequencies were es-
timated using the computer program 3LOCUS.pas (24).
Results
Identification of SNPs
Figure 1 shows an overview of the different SNPs iden-
tified. Previous unpublished studies in our laboratory had
shown a variation at nucleotide position 785 of the D1 cDNA
sequence (GenBank accession no. GI 4557521) which is oc-
cupied by a C or a T. This polymorphism was confirmed in
the dbEST and is referred to as D1a-C/T (Fig. 1). Sequencing
of the region around the SECIS element of the D1 gene
showed an A/G variation in 2 of the 15 subjects at position
1814 (D1b-A/G), 33 nucleotides downstream of the SECIS
element. This variation was confirmed in the dbEST. No
TABLE 3. Conditions used for RFLP and SBE analysis (see Subjects and Methods)
RFLP primers Annealingtemperature
Restriction
enzymes SBE primers
D1a-C/T Fw 5-GAACTTGATGTGAAGGCTGGA-3 54C BclI Fw 5-(T4)GATACCTGAATTCTAGGTGA-3
Rv 5-TAACCTCAGCTGGGAGTTGTTT-3 Rv 5-(T4)CTTGAGAAGCCCTCCCGTTG-3
D1b-A/G Fw 5-CAACAGAGTCATCTAGAAGGGA-3 48C SpeI Fw 5-(T10)TTATAAGATGCAGTAAACTA-3
Rv 5-CACATTTAACATGTAACATAG-3 Rv 5-(T10)ATATTTTCATCATTCTGTTA-3
D2-A/G Fw 5-GATAGTAAAGAATAACAGCCTTGGCT-3 58C RsaI Fw 5-(T16)GTGTGGTGCATGTCTCCAGT-3
Rv 5-CAGCTATCTTCTCCTGGATACCA-3 Rv 5-(T16)ACTGTTGTCACCTCCTTCTG-3
D3-T/G Fw 5-CTGGTAGGGGAAGTGATCTCG-3 60C BssSI Fw 5-(T22)TGGTAGGGGAAGTGATGTCG-3
Rv 5-GCCAATGCCTCTCAAGCTATC-3 Rv 5-(T22)CTGCCCACCCCTCCCCATCC-3
TSHa-G/C Fw 5-ATTTCGGAGGATGGAGAAATA-3 53C Bsp 1286I
Rv 5-GTCTGCGTACTGGGCGGTAA-3
TSHb-C/A Fw 5-GCGATTTCGGAGGATGGAGAAATAGC-3 58C Tth111I Fw 5-(T28)AACGCATCCCCAGCTTACCG-3
Rv 5-CCGGGTACTCACAGAGTCTGCGACCTG-3 Rv 5-(T28)CTTCAGAGTCTGCGTACTGG-3
TSHc-C/G Fw 5-AACGCCAGGCTCAGGCATAC-3 60C NlaIII Fw 5-(T34)GTTCAAAAGGTTACCCACGA-3
Rv 5-AAGTTCCCCTACCATTGTGA-3 Rv 5-(T34)TTGTGGAGACCCTGCCTCAT-3
TR-T/C Fw 5-(T40)AAACACCACGTGACACACTT-3
Rv 5-(T40)TTCATCAGGAGTTTAGGCCA-3
Mismatches are shown by an underscore.
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other SNPs in D1 were found in at least two different
databases.
No variation was detected by sequencing of the region
around the SECIS element of the D2 gene. However, screen-
ing of the dbEST showed a very frequent A/G polymor-
phism at nucleotide 674 of the D2 sequence (GI 13654872),
predicting a change in amino acid 92 of the protein (D2-G/A;
Thr92Ala; Fig. 1).
Sequencing of the coding sequence of the D3 gene showed
no variation in the 15 healthy subjects. However, a T/G
polymorphism was found at position 1546 of the D3 cDNA
sequence (GI 4503334), 66 nucleotides upstream of the SECIS
element (D3-T/G) in 2 of the 15 subjects. This polymorphism
was confirmed in the dbSNP.
Screening of the literature revealed three SNPs in the cod-
ing sequence of the TSHR gene. The Asp36His variation
[TSHRa-G/C polymorphism in nucleotide 206 of the TSHR
cDNA sequence (GI 4507700)] and the Pro52Thr variation
(TSHRb-C/A polymorphism in nucleotide 254) are located in
the extracellular domain of the receptor, whereas the
Asp727Glu variation (TSHRc-C/G polymorphism in nucle-
otide 2281) is situated in the intracellular domain. TSHRb-
C/A and TSHRc-C/G were also identified in the dbSNP.
A silent T/C polymorphism in TR gene (TR-T/C), cor-
responding to position 1536 of the TR1 cDNA sequence (GI
10835122) and to amino acid 412 (Phe) of the TR1 protein,
was found in previous studies in our laboratory (Wassen, F.,
unpublished results).
Figure 2 shows examples of one RFLP analysis and two
SBE analyses. All SBE and RFLP data were concordant, with
the restriction that we could not make a clear distinction by
RFLP between heterozygous D3-GT and homozygous
D3-GG subjects. Frequencies of the different genotypes and
alleles are depicted in Table 4. Except for TSHRa-Asp36His,
all SNPs were frequent enough to perform statistical anal-
ysis. Except for TSHRb-Pro52Thr, all distributions were in
Hardy-Weinberg equilibrium (Table 4).
Association of SNPs with plasma TSH and
iodothyronine levels
D1a is a very frequent polymorphism. The T-allele of D1a
was associated in a dose-dependent manner with increasing
plasma rT3 levels: CC, 0.29  0.01; CT, 0.32  0.01; and TT,
0.34 0.02 nmol/liter (mean se; P 0.017; corresponding to
18.8, 20.8, and 22.1 ng/dl; Fig. 3A). The difference corresponds
to a 33% of sd increase per allele copy. In addition, we observed
FIG. 2. A, RFLP analysis of 10 subjects for D1a-C/T. A PCR fragment
was generated of 565 bp. Incubation with BclI generates two frag-
ments of 434 and 131 bp only in the presence of the D1a-T allele (only
the 565- and 434-bp fragments are shown in this figure). B, SBE
analysis of two subjects for D1a-C/T, D1b-A/G, D2-A/G, D3-T/G. Or-
ange peaks represent the size marker, blue peaks represent a C, green
peaks represent a T, and a black peak represents a G. The reverse
primer was used for D1b-A/G and D2-A/G (see Materials and Meth-
ods). By developing primers of a different size, it is possible to analyze
several SNPs in one SBE reaction. Subject 1 is heterozygous for
D1b-A/G and D2-A/G, whereas subject 2 is heterozygous for D1a-C/T
and D3-T/G.
FIG. 1. The thyroid hormone pathway
genes analyzed in this study and in which
polymorphisms were identified. Nucleotide
numbers are based on the following Gen-
Bank accession no.: 4557521 for D1,
13654872 for D2, 4503334 for D3, 4507700
for TSHR, and 10835122 for TR. Size of the
different exons is indicated by their scale.
The coding sequence is represented by u,
whereaso indicates the UTR. A UGA codon,
coding for SeC, is depicted by […]. Finally,
SECIS elements are indicated by .
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the T-allele to be associated with increasing plasma rT3/T4 ratio
(P  0.01; Fig. 3B) and decreasing plasma T3/rT3 ratio (P 
0.003). The G allele of the D1b-A/G polymorphism was less
frequent and was associated with lower plasma rT3/T4 (P 
0.024) and higher T3/rT3 (P  0.08) ratios. Due to the low
frequency of the polymorphism, the difference in rT3 levels
failed to reach significance (P  0.17; Fig. 3, C and D).
These two D1 SNPs were analyzed for linkage disequi-
FIG. 3. Differences between plasma
rT3 concentrations (A and C) and
plasma rT3/T4 ratios (B and D) by ge-
notype for the D1a (A and B) and D1b (C
and D) polymorphism. P values repre-
sent an ANOVA test (C) or an ANOVA
test for linearity (A and B). To convert
values for rT3 to nanograms per decili-
ter, multiply by 65.1.
TABLE 4. Frequencies of genotypes and alleles for the polymorphisms identified
Polymorphism Genotype frequencies Allele frequency HWE P
D1a-C/T CC CT TT
65 (41.7%) 76 (48.7%) 15 (9.6%) C  66% 0.28
T  34%
D1b-A/G AA AG GG
124 (79.5%) 32 (20.5%) 0 A  89.7% 0.15
G  10.3%
D2-A/G AA AG GG
58 (37.2%) 75 (48.1%) 23 (14.7%) A  61.2% 0.88
G  38.8%
D3-T/G TT TG GG
112 (72.3%) 42 (27.1%) 1 (0.6%) T  85.5% 0.16
G  14.2%
TSHa-G/C GG GC CC
154 (98.7%) 2 (1.3%) 0 G  99.4% 0.94
C  0.6%
TSHb-C/A CC CA AA
139 (89.7%) 14 (9.0%) 2 (1.3%) C  94.2% 0.03
A  5.8%
TSHc-C/G CC CG GG
127 (81.4%) 29 (18.6%) 0 C  90.7% 0.20
G  9.3%
TR-T/C TT TC CC
145 (93.5%) 10 (6.5%) 0 T  96.8% 0.68
C  3.2%
Except for TSHb-C/A, distribution of all genotypes was in Hardy-Weinberg equilibrium (HWE).
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librium, and haplotype allele frequencies were calculated.
The results revealed that there were only three different
haplotype alleles in this population (1  aC-bA, 2  aT-bA,
3  aC-bG, with a frequency of 0.56, 0.34, and 0.10, respec-
tively). On the basis of these three haplotype alleles, all in-
dividuals could be genotyped, and the effect of the individ-
ual alleles on plasma thyroid hormone parameters could be
assessed. The haplotype 1 showed no correlation with rT3,
rT3/T4, or with T3/rT3 ratio. The haplotype 2 showed a
positive correlation with rT3 (P 0.017) and rT3/T4 ratio (P
0.01), and a negative relation with T3/rT3 ratio (P  0.003;
Fig. 4, A and B). Due to the low frequency of the haplotype
allele 3, statistical analysis had limited power. A negative
relation with rT3 (P 0.172) and with rT3/T4 (P 0.024) and
a positive relation with T3/rT3 (P  0.08) was observed.
D2-A/G was the most frequent polymorphism in this
study. No significant correlation was found with plasma
iodothyronine levels in this population. However, plasma
TSH levels were lower in subjects heterozygous for this D2
polymorphism (GA, 1.17 0.08, vs. AA, 1.44 0.11, and GG,
1.49  0.13 mU/liter; P  0.07). Also, the plasma TSH/T4
ratio was lower in heterozygous subjects (P  0.08).
For the D3-T/G polymorphism, the frequency of geno-
types was 72.3% TT, 27.1% TG, and 0.6% GG. No significant
correlation between this polymorphism and plasma iodo-
thyronines was observed.
Only two subjects in this study possessed the TSHRa-His
variant. Therefore, statistical power was limited to analyze
the relation with plasma levels for this polymorphism. No
associations were found for the TSHRb-Pro52Thr polymor-
phism with plasma iodothyronine or TSH levels in this pop-
ulation. For the TSHRc-Asp727Glu polymorphism, heterozy-
gous subjects showed decreased TSH levels (P 0.04; Fig. 5)
and tended to have lower plasma TSH/FT4 (P  0.06),
TSH/T4 (P  0.08), and TSH/T3 (P  0.06) ratios than sub-
jects homozygous for the Asp allele.
No association was found for the TR-T/C polymor-
phism with plasma iodothyronine and TSH levels in our
population.
Functional characterization of D2-Thr92Ala variant
To define the effects of the substitution of the Thr residue
at position 92 in D2 by Ala, expression vectors were made
encoding WT-D2 and D2-Thr92Ala enzyme. Homogenates of
cells, transfected with WT-D2, D2-Thr92Ala, or a 1:1 mixture
of WT-D2 and D2-Thr92Ala enzymes, displayed similar Km
and Vmax values using T4 or rT3 as substrate (Table 5 and
Fig. 6A). Upon incubation of intact transfected cells with
increasing amounts of unlabeled T4, the fractional deiodi-
nation of [125I]T4 decreased in a similar way (Fig. 6B). No
differences in deiodination of T4 were observed between cells
expressing WT-D2, D2-Thr92Ala, or a combination of both.
Discussion
To date, little information has been available regarding the
presence of functionally relevant polymorphisms in thyroid
hormone pathway genes. In this study, we focused on the D1,
D2, D3, TSHR, and TR genes and identified eight polymor-
phisms of interest. Four of them (D2-Thr92Ala, TSHRa-
FIG. 4. Differences in rT3 levels (A) and T3/rT3 ratios (B) in subjects
analyzed by genotype for haplotype alleles for the combined D1a and
D1b polymorphisms (1C–A, 2 T–A, 3C–G). P values represent
an ANOVA test for linearity. To convert values for rT3 to nanograms
per deciliter, multiply by 65.1.
FIG. 5. Difference in plasma TSH concentration between subjects
homozygous for the TSHRc-Asp (TSHRc-C) variant and subjects het-
erozygous for the TSHRc-Asp/Glu (TSHRc-C/G) variants (P  0.05).
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Asp36His, TSHRb-Pro52Thr, and TSHRc-Asp727Glu) have
been reported previously (21, 25–27). This is the first study
that reports the polymorphisms D1a-C/T, D1b-A/G, D3-
T/G, and TR-T/C. Three are located in the 3-UTR of the
deiodinase genes, i.e. D1a-C/T, D1b-A/G, and D3-T/G,
whereas one, TR-T/C, is a silent SNP. No other polymor-
phisms have been reported in any of the three deiodinases
so far.
We found a significant correlation between the D1a-C/T
polymorphism and plasma rT3, with rT3 levels progressively
increasing in subjects with zero, one, or two D1a-T alleles.
The T variant was also positively correlated with the plasma
rT3/T4 ratio, and negatively correlated with the T3/rT3 ratio.
Although the D1b-A/G polymorphism was not significantly
correlated with plasma rT3, the G variant was negatively
correlated with the rT3/T4 ratio and positively with the T3/
rT3 ratio. Liver D1 plays a key role in the production of
plasma T3 from T4 and in the breakdown of the metabolite
rT3 (7, 8). RT3 is by far the preferred substrate for D1 (7, 8).
For this reason, a functionally relevant SNP in D1 is expected
to affect plasma iodothyronine levels, in particular rT3, and
ratios between plasma iodothyronines (7, 8). These data sug-
gest a negative effect of the D1a-T variant on total D1 activity,
whereas the D1b-G variant appears to have a positive effect.
This is supported by the haplotype analysis, which showed
a negative relation of the C-G haplotype allele (haplotype 3)
and a positive relation of the T-A haplotype allele (haplotype
2) with plasma rT3 and rT3/T4 levels. These haplotype alleles
had an opposite effect on plasma T3/rT3 levels. Because both
SNPs are located in the 3-UTR, a change in the stability of
the mRNA is an attractive explanation. Another explanation
may be an altered folding of the mRNA, which–at least at the
site of the SECIS element–is necessary for the incorporation
of the SeC. Alternatively, the association could be explained
by linkage disequilibrium with another SNP located in the
coding sequence or in regulatory areas of the gene, such as
TABLE 5. Kinetic characteristics of D2 enzymes (incubations in presence of 20 mM DTT)
Deiodinase Km (T4)(nM)
Vmax (T4)
(pmol T4/minmg)
Vmax/Km
Km
(rT3) (nM)
Vmax (rT3)
(pmol rT3/minmg) Vmax/Km
D2-WT 4.3/3.1a 0.32/0.61a 0.07/0.20a 17 0.34 0.02
D2-Thr92Ala 5.5/3.1a 0.49/0.69a 0.09/0.22a 19 0.38 0.02
a Results of two separate experiments are shown, using T4 as a substrate.
FIG. 6. A, Lineweaver-Burk plot of T4 deiodination by D2-
WT, D2-Thr92Ala, or D2-WT/D2Thr92Ala (1:1) at 20 mM
DTT in the presence of varying concentrations of T4. B, In
situ deiodination at varying T4 concentrations. COS cells
were transfected with D2-WT, D2-Thr92Ala, or D2-WT/
D2Thr92Ala (1:1) expression vectors, and intact cell deio-
dination was determined as described in Subjects and
Methods.
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the promoter region of the D1 gene. However, in this study
we did not find any evidence for SNPs in the coding sequence
of D1.
We did not see a significant correlation of the D1a and D1b
SNPs with plasma T3 concentration, which can be explained
by the fact that there are many pathways for T3 metabolism,
such as glucuronidation, sulfation, and deiodination by D1
and D3. In addition, there are three sources of plasma T3, i.e.
thyroidal T3 secretion, outer ring deiodination (ORD) of T4
by D1, and ORD of T4 by D2 (7, 28). On the other hand, rT3
turnover is less complicated; it is largely produced by inner
ring deiodination of T4 by D3, and cleared by D1-catalyzed
ORD. This may explain why no correlation was found of the
SNPs in D1 with plasma T3, whereas we did find a significant
correlation with rT3 levels.
Local D2 activity is essential for the negative feedback
regulation of hypophyseal TSH secretion by plasma T4, as
demonstrated in the D2 knockout mouse (19). No significant
effect of the D2-Thr92Ala polymorphism was seen on plasma
TSH levels, iodothyronine levels or their ratios in this healthy
population. However, D2 is particularly important for local
T3 production in D2-containing tissues (7, 8), and on the basis
of this study, it cannot be excluded that intracellular thyroid
hormone levels are affected by this polymorphism.
The D2-Ala92 variant was previously reported to be as-
sociated with insulin resistance (25). However, the functional
consequences of this polymorphism with regard to deiodi-
nase activity were not investigated in this study (25). To
determine the possible functional effects of this polymor-
phism, we performed in vitro analysis of the D2-Thr92Ala
variant by transfection of COS cells. In an attempt to mimic
the heterozygous situation, cells were also transfected with
a combination of both variants. No significant differences in
D2 activity were observed, either when assays were done on
homogenates in the presence of excess DTT as cofactor or in
intact cells in the presence of the natural cofactor of the
enzyme. Whether the previously reported association (25)
can be explained by linkage with another polymorphism and
whether this association can be confirmed in different pop-
ulations should be explored in future studies.
D3 is present in human brain, placenta, skin, and various
fetal tissues, and is the major T4 and T3-inactivating enzyme
by catalyzing their conversion to rT3 and 3.3-T2, respec-
tively. It plays an essential role during fetal development in
which it protects the embryo from excess thyroid hormone
(29). We did not find any effect of the D3-T/G polymorphism
on plasma iodothyronine levels in this population. The ef-
fects of this polymorphism on tissue thyroid hormone levels,
and, thus, for instance on brain development and function,
should be explored in future studies.
The growth and function of the thyroid are controlled by
TSH through its receptor (30). Many mutations in TSHR have
been identified as causes of thyroid diseases (30, 31). In
addition to these mutations, three interesting polymor-
phisms in the coding sequence of the TSHR gene have been
described. TSHRa-Asp36His and TSHRb-Pro52Thr polymor-
phisms are situated in the extracellular domain of the re-
ceptor, whereas the TSHRc-Asp727Glu polymorphism is lo-
cated in the intracellular domain. The His variant of the
TSHRa-Asp36His polymorphism was detected in only two
subjects in our population, indicating an allelic frequency of
less than 1%, which is not significantly different from the
frequency reported by Gustavsson et al. (26). No further
statistical analysis was performed for this polymorphism.
The TSHRb-Pro52Thr polymorphism was more frequent,
with an allelic frequency of the Thr variant of 6%, which is
in agreement with other studies (21, 32). The genotype dis-
tribution of this SNP is not in Hardy-Weinberg equilibrium,
which may be explained by the small size of the groups or
by multiple testing, rather than by population bias. Conflict-
ing observations regarding the response of this variant to
TSH stimulation (33–35) could reflect the subtle effects of this
polymorphism. We found no association of this polymor-
phism with plasma TSH levels, which can be due to the low
frequency of the SNP. This SNP should therefore be analyzed
in future studies in larger populations.
The allele frequency of the Glu variant of the TSHRc-
Asp727Glu polymorphism is 9.5%, in agreement with results
reported by Nogueira et al. (36). Conflicting data have been
obtained regarding the cAMP response to TSH of this variant
receptor in transfection studies (36, 37). No evidence was
found for an association of the TSHRc-Asp727Glu polymor-
phism with nonautoimmune hyperfunctioning thyroid dis-
orders (27). However, we found a significant association of
the TSHRc-727Glu variant with lower plasma TSH levels
and, although not significant, with lower plasma TSH/T4,
and TSH/FT4 ratios. These data agree with findings showing
an increased cAMP response of the TSHRc-Glu variant (37)
to TSH, because less TSH would be required to achieve a
normal thyroid hormone production. Together, these data
suggest that this is a functionally relevant SNP.
We identified a silent polymorphism in the coding se-
quence of the TR gene (T1536C), with an allelic frequency
of the C variant of 3%. No evidence was found in our pop-
ulation for an association of the TR-C/T polymorphism
with plasma TSH or iodothyronine levels, or their ratios. Due
to the low number of subjects with the TR-T variant, no
conclusions can be drawn from our observations regarding
the (lack of) functional importance of this polymorphism.
In conclusion, we have analyzed the possible association of
eight SNPs in five thyroid hormone pathway genes with
plasma TSH and iodothyronine levels. Four of those polymor-
phisms have not been described before. We find significant
effects for three SNPs on plasma TSH and/or thyroid hormone
levels. Due to the low frequency of several other SNPs, no
conclusions can be drawn in our current population about their
effect on plasma TSH and/or thyroid hormone levels.
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